Composition
- Active ingredients
- NINTEDANIB EQ 150MG BASE
Strengths and forms
The FDA lists each strength of a product separately; these pages share one label.
- NINTEDANIB 100MG · CapsuleANDA218472-002 · Tentative approval
- NINTEDANIB 25MG · CapsuleANDA218472-003 · Tentative approval
- NINTEDANIB 100MG · CapsuleANDA219708-002 · Tentative approval
- NINTEDANIB 100MG · CapsuleANDA219371-002 · Tentative approval
- NINTEDANIB 25MG · CapsuleANDA219371-003 · Tentative approval
- NINTEDANIB EQ 150MG BASE · CapsuleThis page
- NINTEDANIB EQ 100MG BASE · CapsuleANDA212732-001 · Tentative approval
- NINTEDANIB EQ 150MG BASE · CapsuleANDA215123-002 · Tentative approval
Official product information
Drugs@FDA lists the approved labels, letters and reviews for application ANDA212732.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Brand name
- Nintedanib
- Route
- Oral
- Dosage form
- Capsule
- Applicant
- Accord Hlthcare Inc
- Status
- Tentative approval
- FDA approval
- 4 Aug 2020
- Application
- ANDA212732-002